



# Stabilis



## Imipenem - cilastatin sodium



Noms commerciaux

Acigfacil	Mexique
Andatin	Danemark, Norvège
Arzomeba	Chili
Bacure	Equateur, Maroc, Pérou
Betatrexil	Equateur
Cilanem	Chili
Cilapem	Turquie
Conet	Slovénie
Gimipen	Colombie
Imacina	Chili
Imipen	Italie
Imistatin	Argentine
Linataz	Colombie
Perloyem	Argentine
Primaxin	Australie, Canada, Etats Unis d'Amérique, Grande Bretagne, Grèce, Nouvelle Zélande, Pérou
Silanem	Turquie
Silpen	Chili
Tenacid	Italie
Tesilan	Colombie
Tienam	Afrique du sud, Allemagne, Arabie Saoudite, Belgique, Chili, Colombie, Croatie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Finlande, France, Hongrie, Iran, Irlande, Italie, Luxembourg, Malaisie, Maroc, Mexique, Norvège, Pays bas, Pérou, Pologne, Portugal, Roumanie, Suède, Suisse, Thaïlande, Tunisie, Turquie
Zienam	Allemagne, Argentine, Autriche, Vénézuela



### Stabilité des solutions

Icon 1	Icon 2	Icon 3	Icon 4	Icon 5	Icon 6	Icon 7	Icon 8	Icon 9
		2.5 mg/ml	4°C		72			21
		2.5 & 5 mg/ml	25°C		9			21

		5 mg/ml	4°C		48				21
		2.5 mg/ml	4°C		72				21
		2.5 & 5 mg/ml	25°C		9				21
		5 mg/ml	4°C		48				21
		2.5 mg/ml	25°C		6				21
		2.5 & 5 mg/ml	4°C		24				21
		5 mg/ml	25°C		3				21
	RL	2.5 mg/ml	25°C		6				21
	RL	2.5 & 5 mg/ml	4°C		24				21
	RL	5 mg/ml	25°C		3				21
		2.5 & 5 mg/ml	25°C		3				21
		2.5 & 5 mg/ml	4°C		24				21
PE		2,5 mg/ml	22°C		24				1067
PE		2,5 mg/ml	4°C		24				1067
EVA		2,5 & 5 mg/ml	4°C		3				1811
PI		5 mg/ml	25°C		24				604
PI		5 mg/ml	4°C		3				604
?		8 mg/ml	25°C		3				2042
?		8 mg/ml	37°C		2				2042
?		5 mg/ml	2-8°C		8				4298
?		5 mg/ml	23-27°C		4				4298


































































### Facteur influençant la stabilité

					898
					1103
	NaH CO3				21
	-20°C				150
	-20°C				21
					21



## Compatibilités

			
		Imipenem - cilastatin sodium	 21
		Imipenem - cilastatin sodium : 0.5 mg/ml	 1103
		Imipenem - cilastatin sodium	 3530
		Imipenem - cilastatin sodium : 5 mg/ml	 4440
		Imipenem - cilastatin sodium : 10 mg/ml	 1415
		Imipenem - cilastatin sodium : 5/5 mg/ml Aciclovir sodium : 5 mg/ml	 336
		Imipenem - cilastatin sodium : 5 mg/ml	 898
		Imipenem - cilastatin sodium : 10 mg/ml Allopurinol sodium : 3 mg/ml	 307
		Imipenem - cilastatin sodium : 10 mg/ml Amifostine : 10 mg/ml	 3
		Imipenem - cilastatin sodium Amikacin sulfate	3549
		Imipenem - cilastatin sodium : 5 mg/ml Amiodarone hydrochloride : 6 mg/ml	 1611
		Imipenem - cilastatin sodium : 4/4 mg/ml Amoxicillin sodium : 8 mg/ml	 2349
		Imipenem - cilastatin sodium : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	3824
		Imipenem - cilastatin sodium : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	 921
		Imipenem - cilastatin sodium : 5 mg/ml Anidulafungin : 0.5 mg/ml	 1982
		Imipenem - cilastatin sodium : 5 mg/ml Azithromycine : 2 mg/ml	 1800
		Imipenem - cilastatin sodium : 10 mg/ml Aztreonam : 40 mg/ml	 99
		Imipenem - cilastatin sodium : 5 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml	 3976
		Imipenem - cilastatin sodium : 5 mg/ml Caspofungin acetate : 0,7 mg/ml	 2247
		Imipenem - cilastatin sodium : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 4528
		Imipenem - cilastatin sodium : 50 mg/ml Cefoxitin sodium : 100 mg/ml	4389
		Imipenem - cilastatin sodium : 5/5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	 3828
		Imipenem - cilastatin sodium : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	 299
		Imipenem - cilastatin sodium : 5/5 mg/ml Colistin mesilate sodium : 1.5 mg/ml	 3997
		Imipenem - cilastatin sodium	 3985

		Imipenem - cilastatin sodium : 9.94/9.94 mg/ml Defibrotide : 8 mg/ml		3728
		Imipenem - cilastatin sodium : 5 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Imipenem - cilastatin sodium : 10 mg/ml		301
		Imipenem - cilastatin sodium : 9.94/9.94 mg/ml Defibrotide : 8 mg/ml		3728
		Imipenem - cilastatin sodium : 10 mg/ml Docetaxel : 0.9 mg/ml		1754
		Imipenem - cilastatin sodium : 5 mg/ml Enalaprilate : 0.0125 mg/ml		1703
		Imipenem - cilastatin sodium : 5/5 mg/ml Eravacycline : 0,6 mg/ml		4434
		Imipenem - cilastatin sodium Erythromycin lactobionate		3674
		Imipenem - cilastatin sodium : 10 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Imipenem - cilastatin sodium : 10 mg/ml Famotidine		397
		Imipenem - cilastatin sodium : 10 mg/ml Filgrastim : 30 µg/ml		244
		Imipenem - cilastatin sodium : 5/5 mg/ml Filgrastim : 40 µg/ml		104
		Imipenem - cilastatin sodium : 10 mg/ml Fluconazole : 2 mg/ml		496
		Imipenem - cilastatin sodium : 5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Imipenem - cilastatin sodium : 5 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Imipenem - cilastatin sodium : 10 mg/ml Foscarnet sodium : 24 mg/ml		73
		Imipenem - cilastatin sodium : 5/5 mg/ml Fosfomycin : 30 mg/ml		4055
		Imipenem - cilastatin sodium : 5/5 mg/ml Gallium nitrate : 1 mg/ml		91
		Imipenem - cilastatin sodium : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Imipenem - cilastatin sodium : 10 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Imipenem - cilastatin sodium : 5 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Imipenem - cilastatin sodium : 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Imipenem - cilastatin sodium : 5/5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Imipenem - cilastatin sodium : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Imipenem - cilastatin sodium : 10 mg/ml Linezolid : 2 mg/ml		1925
		Imipenem - cilastatin sodium : 5 mg/ml Lorazepam : 0.33 mg/ml		186

		Imipenem - cilastatin sodium : 10 mg/ml Melphalan : 0.1 mg/ml		169
		Imipenem - cilastatin sodium : 50 mg/ml Meropenem : 50 mg/ml		4319
		Imipenem - cilastatin sodium : 5 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Imipenem - cilastatin sodium : 5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Imipenem - cilastatin sodium : 50 mg/ml Paracetamol : 10 mg/ml		4742
		Imipenem - cilastatin sodium : 5 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Imipenem - cilastatin sodium : 2,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Imipenem - cilastatin sodium : 5/5 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Imipenem - cilastatin sodium : 10 mg/ml Propofol : 10 mg/ml		300
		Imipenem - cilastatin sodium : 5 mg/ml Propofol		660
		Imipenem - cilastatin sodium : 10 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Imipenem - cilastatin sodium : 5 mg/ml Sargramostim : 10 µg/ml		335
		Imipenem - cilastatin sodium : 250 & 500 mg/ml Sodium bicarbonate : 50 mg/ml		21
		Imipenem - cilastatin sodium : 5/5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Imipenem - cilastatin sodium : 10 mg/ml Tacrolimus : 1000 µg/ml		479
		Imipenem - cilastatin sodium : 5/5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Imipenem - cilastatin sodium : 5/5 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Imipenem - cilastatin sodium : 5/5 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Imipenem - cilastatin sodium : 5/5 mg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
		Imipenem - cilastatin sodium Temocilline		4470
		Imipenem - cilastatin sodium : 10 mg/ml Teniposide : 0.1 mg/ml		905
		Imipenem - cilastatin sodium : 10 mg/ml Thiotepa : 1 mg/ml		249
		Imipenem - cilastatin sodium : 5/5 mg/ml Vasopressin : 0.2 UI/ml		2017
		Imipenem - cilastatin sodium : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Imipenem - cilastatin sodium : 5 mg/ml Zidovudine : 4 mg/ml		337



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
21	Revue	Bigley FP, Forsyth RJ, Henley MW. Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm 1986 ; 43: 2803-2809.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Revue	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.

198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998

660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
898	Revue	Zaccardelli DS, Sanders Kromarik C, Wolk R, Khalidi N. Stability of imipenem and cilastatin sodium in total parenteral nutrient solution. JPEN 1990 ; 14: 306-309.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1103	Revue	Fox AS, Boyer KM, Sweeney HM. Antibiotic stability in a pediatric parenteral alimentation solution. J Pediatr 1988 ; 112: 813-817.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten Arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1811	Revue	Trissel LA, Xu QA. Stability of imipenem-cilastatin sodium in autodose infusion system bags. Hosp Pharm 2003 ; 38: 130-134.






























































1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2042	Revue	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal $\beta$ -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2349	Revue	Pourroy B, Milano Bausset E, Boulamery A, Gauthier Villano L, Braguer B. Incompatibility of imipenem–cilastatin and amoxicillin Am J Health-Syst Pharm 2009 ; 66: 1253-1254.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3530	Laboratoire	Imipenem/Cilastatin – Summary of Product Characteristics Hospira 2013
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhani R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apiph Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218

3985	Poster	Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. Hopipharm Congress 2017 - Nancy 2017
3997	Revue	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4298	Revue	Fabio de Souza Barbosa F, Capra Pezzi L, Tsao M, Franco de Oliveira T, Dias Macedo S.M, Schapoval E.E.S, Mendez A.S.L. Stability and degradation products of imipenem applying High-Resolution Mass Spectrometry: an analytical study focused on solutions for infusion. Biomed Chromatogr 2019 ; 33, 4:e4471
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosiimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



# Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 A l'abri de la lumière
 Heure	 Non précisée
 Chlorure de sodium 0,9%	 Glucose 5%
<b>RL</b> Ringer lactate	 Glucose 10%
 Polyéthylène	 NaCl 0,9% ou glucose 5%
 Ethylène vinyl acétate	 Jour
 Elastomère en polyisoprène	 Elastomère (non précisé)
 Non précisé	 Facteur influençant la stabilité
 Solvant	 Nutrition parentérale (mélange binaire)
 Provoque	 Dégradation
 NaHCO <sub>3</sub>	 Diminution
 Augmentation stabilité	 Compatibilités
 Molécule	 Instabilité chimique
 Incompatible	 Incompatibilité non précisée
 Compatible	 Nutrition parentérale (mélange ternaire)
 Changement de couleur	 Précipitation en 1 heure
 Turbidité immédiate	 Changement de couleur après 2 heures
 Précipitation immédiate	 Changement de couleur à 4 heures
 Aucun	 Changement de couleur après 1 heure
 Précipitation en 24 heures	 Turbidité en 4 heures
 Turbidité à 24 heures	 Instabilité de l'émulsion immédiate
 Précipitation en 4 heures	 Turbidité en 1 heure
 Voie d'administration	 Perfusion intraveineuse



Intramusculaire



Bibliographie



Dictionnaire